Phase 1, single‐dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Thrombosis and Haemostasis"
DOI: 10.1111/jth.14247
Abstract: Essentials Marzeptacog alfa (activated) [MarzAA] is a novel variant of activated human factor VII. A phase 1 dose escalation trial of MarzAA was conducted in subjects with severe hemophilia. MarzAA was safe and tolerated at… read more here.
Keywords: marzeptacog alfa; severe hemophilia; phase; alfa activated ... See more keywords